Literature DB >> 1711079

Effect of genistein, a tyrosine kinase inhibitor, on latent EBV activation induced by cross-linkage of membrane IgG in Akata B cells.

M Daibata1, I Mellinghoff, S Takagi, R E Humphreys, T Sairenji.   

Abstract

The activation of phosphoprotein tyrosine kinases was studied in the regulation of EBV activation in Akata cells after cross-linking membrane IgG with anti-IgG. Protein tyrosine phosphorylation was induced in Akata cells after stimulation with anti-IgG, as determined by immunoblotting with the PY20 anti-phosphotyrosine mAb. The frequency of phosphotyrosine-activated cells was also measured by immunofluorescence with the PY20 antibody. Genistein, an inhibitor of tyrosine kinases, at non-cytotoxic doses blocked EBV activation, as measured in the induction of EBV Ag, EBV immediate early BZLF1 mRNA, and its protein product ZEBRA. Such inhibitions were reversed upon removing genistein from the cultures. Genistein inhibition of early Ag induction depended upon the time of addition of genistein after stimulation with anti-IgG. These findings indicate that activation of tyrosine kinase is required for EBV activation after cross-linking membrane IgG in Akata cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711079

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Identification of protein tyrosine kinases required for B-cell- receptor-mediated activation of an Epstein-Barr Virus immediate-early gene promoter.

Authors:  Sandra Lavens; Emmanuel A Faust; Fang Lu; Michele Jacob; Messele Leta; Paul M Lieberman; Ellen Puré
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

2.  Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation.

Authors:  Makoto Fukuda; Richard Longnecker
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  The interaction of mitogen-activated protein kinases to Epstein-Barr virus activation in Akata cells.

Authors:  T Satoh; Y Hoshikawa; Y Satoh; T Kurata; T Sairenji
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

4.  Complete nucleotide sequence of bean pod mottle virus RNA1: sequence comparisons and evolutionary relationships to other comoviruses.

Authors:  R Di; C C Hu; S A Ghabrial
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

5.  Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency.

Authors:  Helen Bryant; Paul J Farrell
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking.

Authors:  C L Miller; J H Lee; E Kieff; R Longnecker
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

7.  Predominant expression and activation-induced tyrosine phosphorylation of phospholipase C-gamma 2 in B lymphocytes.

Authors:  K M Coggeshall; J C McHugh; A Altman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

8.  Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients.

Authors:  Yoshifumi Nagata; Hiroko Inoue; Koichi Yamada; Hiroyuki Higashiyama; Kenji Mishima; Yasuhiro Kizu; Ienaka Takeda; Fumio Mizuno; Yoshio Hayashi; Ichiro Saito
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

9.  Emodin Inhibits EBV Reactivation and Represses NPC Tumorigenesis.

Authors:  Chung-Chun Wu; Mei-Shu Chen; Yu-Jhen Cheng; Ying-Chieh Ko; Su-Fang Lin; Ing-Ming Chiu; Jen-Yang Chen
Journal:  Cancers (Basel)       Date:  2019-11-15       Impact factor: 6.639

Review 10.  Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies.

Authors:  Hongde Li; Jianmin Hu; Xiangjian Luo; Ann M Bode; Zigang Dong; Ya Cao
Journal:  Cancer Sci       Date:  2018-06-13       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.